Venous Thromboembolism Treatment Market Sees Increasing Adoption of Direct Oral Anticoagulants
The global venous thromboembolism (VTE) treatment market is projected to reach a valuation of US$2.9 billion by the end of 2031, rising from an estimated US$2.2 billion in 2024. This reflects a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031, indicating steady expansion driven by advancements in drug development, diagnostic technologies, and digital health integration. With a historical CAGR of 3.6% between 2018 and 2023, the market’s evolution is a response to increasing prevalence of VTE and the continuous need for effective, safe, and convenient treatment options.